Mary Figaro
Endocrinology, Diabetes & Metabolism · Davenport, IANPI 1710908181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,318 of the $73,014 with a category attached, or 82.6%. 15 manufacturers reported payments, led by Novo Nordisk at 49.0% of the total. Reporting peaked in 2019 at $36,633 and has fallen 97.7% since, to $829 in 2025. Among endocrinology, diabetes & metabolism clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $412.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$36K
- Boehringer Ingelheim$14K
- AstraZeneca$12K
- Lilly USA, LLC$10K
- Abbott$737
- Astellas Pharma US Inc$103
- plus $205 from 9 others
What the payments were for
- Consulting fees$6,2809%
- Speaking & faculty fees$60,31883%
- Travel & lodging$3,6735%
- Food & beverage$2,7114%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $35,812 |
| Boehringer Ingelheim | 28 | $14,032 |
| AstraZeneca | 19 | $11,804 |
| Lilly USA, LLC | 24 | $10,322 |
| Abbott | 43 | $737 |
| Astellas Pharma US Inc | 1 | $103 |
| Dexcom, Inc. | 2 | $34 |
| Valeritas, Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Shire North American Group Inc | 2 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Corcept Therapeutics | 1 | $14 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$23,755
- Ozempic$12,756
- FARXIGA$11,480
- RYBELSUS$9,987
- Tresiba$9,559
- Xultophy 100/3.6$1,755
- FREESTYLE LIBRE 3$124
- Veozah$103
How this compares
$73,014 in reported general payments places this provider in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $65,325 |
| JardianceEmpagliflozin | 39 | $62,882 |
| Novolog FlexpenInsulin Aspart | 34 | $29,670 |
| SynjardyEmpagliflozin/Metformin Hcl | 22 | $23,066 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $16,347 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $14,481 |
| Gvoke Hypopen 2-PackGlucagon | 19 | $11,732 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 29 | $5,014 |
| Liothyronine Sodium | 64 | $3,651 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,984 |
| Levothyroxine Sodium | 162 | $1,631 |
| Dutasteride | 16 | $578 |
| Estradiol | 24 | $517 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 15 | $354 |
| Lisinopril | 29 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $14,032 | $85,94961 claims |
| Novo NordiskOzempic | $35,812 | $65,32534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Davenport
- Ayotunde DokunIowa City$31K
- Anuj BhargavaDes Moines$30K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
- Teck KhooDes Moines$6K
- Rami AlmokayyadAmes$3K
- Amie OgunsakinIowa City$2K
- Fnu DeepikaWaterloo$2K
- Joseph DillonIowa City$2K
- Ronald IversonDubuque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.